Search the Newsreel

FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 3,777,851.04 shares of Mirum Pharmaceuticals Inc. (MIRM) common stock, which represents 6.2% of the class. Abigail P. Johnson also holds sole dispositive power over the same number of shares. The filing indicates …

MIRA's obesity candidate shows rapid absorption in 7-day dog study

MIRA Pharmaceuticals reported positive toxicokinetic results from a 7-day repeated-dose study of its obesity candidate, SKNY-1, in Beagle dogs. The study showed rapid absorption, dose-dependent systemic exposure, and systemic accumulation, which de-risks dose selection for planned GLP toxicology studies. These findings support the advancement …

Admiral reports resilient first-half performance as growth and shareholder returns remain in focus

Scotts Miracle Gro (SMG) Could Be 18% Undervalued As SMG 2.0 Takes Shape

Mirum Pharmaceuticals Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals reported strong Q2 2026 results, with net product sales of $176 million, and raised its full-year guidance to $680 million-$700 million. The company is preparing for the potential Q4 U.S. launch of zilurgisertib for FOP, following a favorable FDA meeting. However, the …

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

Shares of Mirum Pharmaceuticals (MIRM) dropped 15% after the FDA requested an additional Phase 3 trial for its lead candidate, Volixibat, delaying its potential new drug application until the first half of 2027. Despite this setback, the company raised its full-year 2026 net product …

Mirum Pharmaceuticals earnings missed by $0.32, revenue topped estimates

Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

Mirum Pharmaceuticals, Inc. (MIRM) reported $176.24 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 37.9%. EPS of -$0.80 for the same period compares to -$0.12 a year ago. The reported revenue represents a surprise of +6.97% over the …

Mirum Pharmaceuticals (Nasdaq: MIRM) takes $857M H1 2026 net loss

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC - Pre-NDA meeting held for volixibat in …

Mirum Pharmaceuticals (MIRM) SVP sells 1,840 shares under 10b5-1 plan

Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals (MIRM), sold 1,840 shares of common stock on August 3, 2026, at a price of $105.29 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following …

Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez

This article is a filing document from Telomir Pharmaceuticals, specifically a Statement of changes in beneficial ownership of securities. It concerns Officer Aminov Erez and details modifications to their security holdings within the company.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Scotts Miracle-Gro

Faruqi & Faruqi, LLP is investigating potential securities claims against The Scotts Miracle-Gro Company (NYSE: SMG) on behalf of investors who suffered losses exceeding $100,000 between November 3, 2021, and August 1, 2023. The firm alleges that Scotts made false or misleading statements regarding …

Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2026

Mirum Pharmaceuticals (MIRM) announced its Q2 2026 earnings on August 5, 2026, reporting an EPS of -$1.06, missing the consensus estimate of -$0.74. Despite the EPS miss, quarterly revenue increased by 37.9% year-over-year to $176.24 million, exceeding the consensus estimate of $166.33 million. The …

Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mira Pharmaceuticals Inc (MIRA) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.10. Analysts provide a consensus price target of $3.00, suggesting a significant upside of +109.79%. There are no analysts providing individual ratings for MIRA as …

Mirum Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares Fall

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Mirrabooka Investments (ASX:MIR) Dividend Review: A 5.57% Yield from an Australian Equity Portfolio

Inside Mirvac Group’s (ASX:MGR) Dividend Story: What Investors Should Know About Its REIT Exposure

SMG Q3 Earnings Beat on Bonnie Plants JV Strength, Revenues Miss

The Scotts Miracle-Gro Company SMG reported third-quarter fiscal 2026 (ended June 27, 2026) adjusted earnings of $2.82 per share, up 7.6% year over year. The figure beat the Zacks Consensus Estimate of $2.53 by 11.5%, aided by stronger results from the Bonnie Plants joint …

Perma-Fix and Mirion Technologies Form Strategic Partnership for DOE and Federal Nuclear Cleanup Opportunities

Perma-Fix Environmental Services, Inc ATLANTA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI), a global leader in nuclear waste management and environmental remediation solutions, announced today the formation of a strategic Partnership with Mirion Technologies, under the Small Business Administration's …

The Scotts Miracle-Gro Company Outlines Mid-Range Financial Targets For Next 3 Years

(RTTNews) - Tuesday, The Scotts Miracle-Gro Company (SMG) announced its mid-range financial targets for fiscal 2027 through fiscal 2029, expecting to drive sustainable mid- and long-term value for the company and shareholders. The company's mid-range growth algorithm for fiscal 2027 through fiscal 2029 is …

ScottsMiracle-Gro Announces Financial Targets and Capital Allocation Strategy During Investor Day 2026 at NYSE

Scotts Miracle-Gro Company (The) NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, today announced its mid-range financial targets and capital allocation strategy for fiscal 2027 …

Scotts Miracle-Gro’s (SMG) Margin Squeeze: Does a Steady Dividend Mask Deeper Profitability Strains?

Jammu & Kashmir Bank Ltd. Revenue Breakdown – NSE:J&KBANK

Mirion’s Q2 Earnings Call: Our Top 5 Analyst Questions

MIRM (NASDAQ: MIRM) holder files notice to sell common shares

A holder of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) common stock has filed a notice to sell 1,840 shares through Morgan Stanley Smith Barney LLC on or after August 3, 2026. The filing also reports prior sales by Jolanda Marie Howe, including 2,721 shares on …

Stifel raises Scotts Miracle-Gro stock price target on earnings upside

Why Mirion Technologies (MIR) Is Down 9.4% After Reaffirming 2026 Growth Guidance And Robust Backlog

Miramar Hotel Sets August Board Meeting to Approve Interim Results and Dividend

Mirum Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) generated $521.31 million in revenue last year, primarily from its Pharmaceutical segment. This represents an increase from $336.41 million in the previous year. The United States was the largest contributor to revenue, accounting for $401.55 million last year.

MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA

This article provides a basic overview of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) and directs users to financial data on TradingView. It indicates that the market is closed with no trades and points to various financial sections like statements, statistics, dividends, and earnings. The article …

Admiral Group plc Revenue Breakdown – LSE:ADM

Tangible book value per share of MIRA Pharmaceuticals, Inc. – MUN:K6S

This article provides the tangible book value per share for MIRA Pharmaceuticals, Inc. (MUN:K6S) as listed on the Munich Stock Exchange. It indicates that the market was closed at the time of publication and no trades had occurred. The information is presented within a …

MIRM5806400 Bond Coupon Profile — Rate & Payments

This page provides the bond coupon profile for Mirum Pharmaceuticals, Inc. (MIRM5806400), detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.00%, with the next payment planned for November 2, 2026. It offers an overview of the bond's …